Target intelligence / Profile preview

Human immunodeficiency virus type 1 Gag-Pol-Env-Nef polyprotein complex (HIV-1 Gag/Pol/Env/Nef)

Target
HIV-1 Gag/Pol/Env/Nef
Molecular classification
Viral protein, Antigen, Enzyme, Structural protein
01

Overview

HIV-1 Gag/Pol/Env/Nef represents a composite set of the primary structural, enzymatic, and regulatory proteins of the Human Immunodeficiency Virus type 1. Gag provides the structural framework for the virus, including the capsid and matrix, while Pol encodes essential enzymes such as reverse transcriptase, protease, and integrase. Env consists of the surface glycoproteins gp120 and gp41, which are critical for viral attachment and entry into CD4+ T-cells. Nef is an accessory protein that enhances viral replication and promotes immune evasion by downregulating MHC-I and CD4 molecules on the host cell surface. In therapeutic development, this combination is typically used as an antigenic payload in DNA vaccines or viral vectors to stimulate a broad-spectrum immune response. The goal of targeting these proteins collectively is to induce potent CD8+ cytotoxic T-lymphocyte and CD4+ helper T-cell responses capable of controlling viral replication. This multi-antigen approach is designed to minimize the risk of viral escape mutations, which frequently occur when targeting single epitopes.

Other names
HIV-1 polyproteinsGag-Pol-Env-Nef fusion antigenHIV-1 structural and regulatory proteinsHIV-1 Gag/Pol/NefHIV-1 Gag/Pol/Env
02

Mechanism of action

Induction of host-mediated cellular and humoral immune responses against multiple HIV-1 viral components to suppress viral replication and eliminate infected cells.

03

Biological functions

Viral replicationViral assemblyViral entryImmune evasionPolyprotein processing
04

Disease associations

InfectionAcquired Immunodeficiency Syndrome (AIDS)
05

Safety considerations

Vector-induced immunogenicityPotential for increased susceptibility to infection (as observed in the STEP trial)Immune exhaustionInsertional mutagenesis (for DNA or viral vectors)
06

Interacting drugs

VRC-HIVDNA016-00-VP

4 more in the full profile.

07

Biomarkers

HIV-1 RNA viral loadCD4+ T-lymphocyte countIFN-gamma ELISpot responseIntracellular cytokine staining (ICS)HIV-specific antibody titers

Beyond the preview

Go deeper on Human immunodeficiency virus type 1 Gag-Pol-Env-Nef polyprotein complex (HIV-1 Gag/Pol/Env/Nef).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human immunodeficiency virus type 1 Gag-Pol-Env-Nef polyprotein complex (HIV-1 Gag/Pol/Env/Nef).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call